Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23934210 | 0.86 | KMT2A (0.51) | KMT2AMEN1CTDSP1CASP3LMNA | |
| SCHEMBL23934277 | 0.84 | KMT2A (0.49) | KMT2AMEN1NPC1RAB9AESR1 | |
| SCHEMBL23934221 | 0.84 | CASP3 (0.60) | KMT2AMEN1NPC1RAB9ACTDSP1 | |
| SCHEMBL23934284 | 0.82 | MAPT (0.53) | KMT2AMEN1NPC1RAB9ATLK2 | |
| SCHEMBL12635983 | 0.81 | KMT2A (0.69) | KMT2AMEN1NPC1RAB9ATLK2 | |
| SCHEMBL23934276 | 0.80 | CASP3 (0.65) | KMT2AMEN1NPC1RAB9ACTDSP1 | |
| SCHEMBL23934209 | 0.80 | RXFP1 (0.47) | KMT2AMEN1NPC1RAB9ACTDSP1 | |
| SCHEMBL23923273 | 0.78 | RXFP1 (0.55) | KMT2AMEN1CTDSP1CASP3BRAF | |
| SCHEMBL23934203 | 0.77 | POLB (0.54) | KMT2AMEN1NPC1RAB9ACTDSP1 | |
| SCHEMBL23934211 | 0.76 | BRAF (0.54) | KMT2AMEN1NPC1RAB9ACTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912660-B2 | S6K1 protein kinase inhibitors as cancer therapeutics | XAVIER UNIVERSITY OF LOUISIANA (US) | 2024-02-27 | — | — | US | disclosed |
| US-20210323919-A1 | S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS | XAVIER UNIVERSITY OF LOUISIANA | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323919-A1 | S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS | RPS6KA6, RPS6KA1, RPS6KA3 | KMT2A 2003/4885MEN1 2490/4885NPC1 3562/4885 |
| US-11912660-B2 | S6K1 protein kinase inhibitors as cancer therapeutics | RPS6KA6, RPS6KA1, RPS6KA3 | KMT2A 2003/4885MEN1 2490/4885NPC1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.